Mitigating the threat of artemisinin resistance in Africa: Improvement of drug-resistance surveillance and response systems

The Lancet Infectious Diseases

Volumn 12, Issue 11, 2012, Pages 888-896

  Talisuna, Ambrose O ^a,b,c   Karema, Corine ^d   Ogutu, Bernhards ^e   Juma, Elizabeth ^e   Logedi, John ^f   Nyandigisi, Andrew ^f   Mulenga, Modest ^g   Mbacham, Wilfred F ^h   Roper, Cally ⁱ   Guerin, Philippe J ^b,c   D'Alessandro, Umberto ^a,b,j,k   Snow, Robert W ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WorldWide Antimalarial Resistance Network   (United Kingdom)

^d RWANDA BIOMEDICAL CENTER   (Rwanda)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f MINISTRY OF HEALTH   (Kenya)

^g Tropical Diseases Research Centre Ndola   (Zambia)

^h UNIVERSITY OF YAOUNDÉ I   (Cameroon)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Medical Research Council Unit   (Gambia)

^k INSTITUTE OF TROPICAL MEDICINE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE; CHLOROQUINE; FOLIC ACID ANTAGONIST; PYRIMETHAMINE PLUS SULFADOXINE;

AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIMALARIAL DRUG RESISTANCE; DRUG SURVEILLANCE PROGRAM; DRUG USE; ENDEMIC DISEASE; FACTORIAL ANALYSIS; GHANA; HIGH RISK POPULATION; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEDICAL INFORMATION SYSTEM; NOTE; PARASITE CLEARANCE; PARASITEMIA; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SENTINEL SURVEILLANCE; SOUTHEAST ASIA; TANZANIA; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 84867909903     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70241-4     Document Type: Note

References (78)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434:214-217.
2. World Malaria Report 2011 2011, WHO, World Health Organization, Geneva, (accessed Feb 1, 2012). http://www.who.int/malaria/world_malaria_report_2011/9789241564403_eng.pdf.
3. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993, 167:932-937.
4. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 2003, 8:860-867. East African Network for Monitoring Antimalarial Treatment (EANMAT).
5. Talisuna AO, Bloland P, D'Alessandro U History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17:235-254.
6. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999, 353:1965-1967.
7. Antimalarial drug combination therapy-report of a WHO technical consultation, 4-5 April 2001 2001, WHO, World Health Organization, Geneva, (accessed Feb 1, 2012). http://www.who.int/malaria/publications/atoz/who_cds_rbm_2001_35/en/index.html.
8. Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004, 363:237-240.
9. Guidelines for the treatment of malaria 2010, WHO, World Health Organization, Geneva, (accessed Feb 1, 2012). http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html, 2nd edn.
10. Williams HA, Durrheim D, Shretta R The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan 2004, 19:356-370.
11. Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ 2005, 331:734.
12. Malik EM, Mohamed TA, Elmardi KA, et al. From chloroquine to artemisinin-based combination therapy: the Sudanese experience. Malar J 2006, 5:65.
13. Mulligan JA, Mandike R, Palmer N, et al. The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health 2006, 11:452-461.
14. Amin AA, Zurovac D, Kangwana BB, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 2007, 6:72.
15. Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia. Malar J 2008, 7:25.
16. Zurovac D, Tibenderana JK, Nankabirwa J, et al. Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J 2008, 7:181.
17. Tren R, Hess K, Bate R Drug procurement, the Global Fund and misguided competition policies. Malar J 2009, 8:305.
18. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 2004, 71:179-186.
19. Lemeshow S, Taber S Lot quality assurance sampling: single- and double-sampling plans. World Health Stat Q 1991, 44:115-132.
20. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission (WHO/MAL/96.1077) 1996, WHO, World Health Organization, Geneva and Brazzaville.
21. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010, 8:272-280.
22. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012, 379:1960-1966.
23. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012, 336:79-82.
24. International Health Regulations (2005) 2008, WHO, World Health Organization, Geneva, (accessed Feb 1, 2012). http://whqlibdoc.who.int/publications/2008/9789241580410_eng.pdf, 2nd edn.
25. Global plan for artemisinin resistance containment (GPARC) 2011, WHO, World Health Organization, Geneva, (accessed Feb 1, 2012). http://www.who.int/entity/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf.
26. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W, Wernsdorfer W Chemotherapy of malaria, 2nd edn (WHO monograph series 27) 1986, World Health Organization, Geneva.
27. Resistance of malaria parasites to drugs-report of a WHO scientific group (technical report series 296) 1965, WHO, World Health Organization, Geneva.
28. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50) 2003, WHO, World Health Organization, Geneva.
29. Plowe CV, Djimde A, Wellems TE, Diop S, Kouriba B, Doumbo OK Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg 1996, 55:467-471.
30. Nzila AM, Nduati E, Mberu EK, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000, 181:2023-2028.
31. Djimde A, Doumbo OK, Steketee RW, Plowe CV Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001, 358:890-891.
32. Dorsey G, Kamya MR, Singh A, Rosenthal PJ Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 2001, 183:1417-1420.
33. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380-388.
34. Talisuna AO, Langi P, Mutabingwa TK, et al. Population-based validation of DHFR gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Trans R Soc Trop Med Hyg 2003, 97:338-342.
35. Imwong M, Dondorp AM, Nosten F, et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2010, 54:2886-2892.
36. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
37. Wellems TE, Panton LJ, Gluzman IY, et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 1990, 345:253-255.
38. Denis MB, Tsuyuoka R, Lim P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 2006, 11:1800-1807.
39. White NJ, Pongtavornpinyo W The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 2003, 270:545-554.
40. Wernsdorfer WH Epidemiology of drug resistance in malaria. Acta Trop 1994, 56:143-156.
41. Malisa AL, Pearce RJ, Abdulla S, et al. Drug coverage in treatment of malaria and the consequences for resistance evolution-evidence from the use of sulphadoxine/pyrimethamine. Malar J 2010, 9:190.
42. Hastings IM, D'Alessandro U Modelling a predictable disaster: the rise and spread of drug-resistant malaria. Parasitol Today 2000, 16:340-347.
43. Hastings IM, Watkins WM, White NJ The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 2002, 357:505-519.
44. Kublin JG, Cortese JF, Njunju EM, et al. Re-emergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003, 187:1870-1875.
45. Nzila AM, Mberu EK, Sulo J, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000, 44:991-996.
46. Mharakurwa S Plasmodium falciparum transmission rate and selection for drug resistance: a vexed association or a key to successful control?. Int J Parasitol 2004, 34:1483-1487.
47. Talisuna AO, Okello PE, Erhart A, Coosemans M, D'Alessandro U Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. Am J Trop Med Hyg 2007, 77:170-180.
48. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CVJ Return of chloroquine-susceptible falciparum malaria in Malawi was a re-expansion of diverse susceptible parasites. J Infect Dis 2010, 202:801-808.
49. Lynch C, Roper C The transit phase of migration: circulation of malaria and its multidrug-resistant forms in Africa. PLoS Med 2011, 8:e1001040.
50. Clyde DF Drug resistance of malaria parasites in Tanzania. East Afr Med J 1966, 43:405-408.
51. Payne D Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 1988, 4:112-115.
52. Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004, 12:1241-1246.
53. Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia-will Africa be next?. PLoS Med 2006, 3:e197.
54. Gardella F, Assi S, Simon F, Bogreau H, et al. Antimalarial drug use in general populations of tropical Africa. Malar J 2008, 7:124.
55. Hodel EM, Genton B, Zanolari B, et al. Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. J Infect Dis 2010, 202:1088-1094.
56. Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418:320-323.
57. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
58. Integrated disease surveillance strategy-a Regional strategy for communicable diseases 1999-2003 1999, WHO Regional Office for Africa, World Health Organization Regional Office for Africa, Harare.
59. Nsubuga P, Brown WG, Groseclose SL, et al. Implementing integrated disease surveillance and response: four African countries' experience, 1998-2005. Glob Public Health 2009, 13:1-17.
60. Nájera JA Prevention and control of malaria epidemics. Parassitologia 1999, 41:339-347.
61. Teklehaimanot HD, Schwartz J, Teklehaimanot A, Lipsitch M Weather-based prediction of Plasmodium falciparum malaria in epidemic-prone regions of Ethiopia II. Weather-based prediction systems perform comparably to early detection systems in identifying times for interventions. Malar J 2004, 3:44.
62. Thomson MC, Doblas-Reyes FJ, Mason SJ, et al. Malaria early warnings based on seasonal climate forecasts from multi-model ensembles. Nature 2006, 439:576-579.
63. Cox J, Abeku T, Beard J, et al. Detecting epidemic malaria, Uganda. Emerg Infect Dis 2007, 13:779-780.
64. Frosch AE, Venkatesan M, Laufer MK Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J 2011, 10:116.
65. Pearce RJ, Pota H, Evehe MS, Bê el-H, et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med 2009, 6:e1000055.
66. Naidoo I, Roper C Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends Parasitol 2010, 26:447-456.
67. Van Geertruyden J-P, Menten J, Colebunders R, Korenromp E, D'Alessandro U The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008, 7:134.
68. Watkins WM, Mberu EK, Winstanley PA, Plowe CV The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997, 13:459-464.
69. Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010, 201:570-579.
70. Zurovac D, Sudoi RK, Akhwale WS, et al. The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial. Lancet 2011, 378:795-803.
71. Zurovac D, Talisuna AO, Snow RW Mobile phone text messaging: tool for malaria control in Africa. PLoS Med 2012, 9:e1001176.
72. Flegg JA, Guerin PJ, White NJ, Stepniewska K Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011, 10:339.
73. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health 2001, 6:891-898. East African Network for Monitoring Antimalarial Treatment (EANMAT).
74. Tatem AJ, Smith DL International population movements and regional Plasmodium falciparum malaria elimination strategies. Proc Natl Acad Sci USA 2010, 107:12222-12227.
75. Eastern African scientists pledge immediate action to confront the threat of malaria drug resistance (press statement, May 25, 2012) Antimalarial Resistance Stakeholders Meeting, (accessed May 25, 2012). https://www.wwarn.org/sites/default/files/AntimalarialStakeholdersMeetingPressStatement250512.pdf.
76. Chan M, Kazatchkine M, Lob-Levyt J, et al. Meeting the demand for results and accountability: a call for action on health data from eight global health agencies. PLoS Med 2010, 7:e1000223.
77. Harinasuta T, Suntharasamai P, Viravan C Chloroquine-resistant falciparum malaria in Thailand. Lancet 1965, 286:657-660.
78. Campbell CC, Chin W, Collins WE, Teutsch SM, Moss DM Chloroquine-resistant Plasmodium falciparum from east Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet 1979, 314:1151-1154.